Join Us Live for a Discussion on Medicare, Democracy, and the Future of Health Care
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
On Monday, the U.S. House of Representatives briefly returned from summer recess to approve the Senate-passed budget resolution. Committees in
President Biden recently outlined his vision for improving prescription drug affordability. His plan calls on Congress to allow Medicare to negotiate drug prices, impose
This week, Senate Democrats passed their $3.5 trillion budget resolution, laying the groundwork for legislation that is expected to include
Medicare Part D, which covers outpatient prescription drugs for people with Medicare, has four phases of coverage: the deductible, when
This week, as Congress continued to discuss strategies to improve health coverage, Medicare Rights weighed in, urging them to prioritize critical
Medicare Rights and other leading beneficiary advocate groups urged the Administration and Congress to keep improvements to the Medicare program central in ongoing discussions about creating a more equitable and affordable health care and prescription drug system.
Congress is currently considering strategies to improve health coverage and affordability. Weigh in today to make sure that Medicare is part
A recent Government Accountability Office (GAO) report found that of the $560 billion that Medicare and people with Medicare spent on prescription
On May 4, the U.S. House Committee on Energy and Commerce, Subcommittee on Health held a hearing on drug pricing legislation, including
Immediate action is needed to transform the nation’s drug pricing system in ways that will lower prices, strengthen Medicare, and promote the well-being of those who rely on its coverage. H.R. 3 would significantly advance these goals, in part by authorizing Medicare to negotiate prices for certain drugs; imposing inflationary rebates; and restructuring Part D to cap beneficiary out-of-pocket costs at $2,000 per year, reduce the federal government’s liability, and better align pricing incentives.
On Monday, the U.S. House of Representatives briefly returned from summer recess to approve the Senate-passed budget resolution. Committees in
President Biden recently outlined his vision for improving prescription drug affordability. His plan calls on Congress to allow Medicare to negotiate drug prices, impose
This week, Senate Democrats passed their $3.5 trillion budget resolution, laying the groundwork for legislation that is expected to include
Medicare Part D, which covers outpatient prescription drugs for people with Medicare, has four phases of coverage: the deductible, when
This week, as Congress continued to discuss strategies to improve health coverage, Medicare Rights weighed in, urging them to prioritize critical
Medicare Rights and other leading beneficiary advocate groups urged the Administration and Congress to keep improvements to the Medicare program central in ongoing discussions about creating a more equitable and affordable health care and prescription drug system.
Congress is currently considering strategies to improve health coverage and affordability. Weigh in today to make sure that Medicare is part
A recent Government Accountability Office (GAO) report found that of the $560 billion that Medicare and people with Medicare spent on prescription
On May 4, the U.S. House Committee on Energy and Commerce, Subcommittee on Health held a hearing on drug pricing legislation, including
Immediate action is needed to transform the nation’s drug pricing system in ways that will lower prices, strengthen Medicare, and promote the well-being of those who rely on its coverage. H.R. 3 would significantly advance these goals, in part by authorizing Medicare to negotiate prices for certain drugs; imposing inflationary rebates; and restructuring Part D to cap beneficiary out-of-pocket costs at $2,000 per year, reduce the federal government’s liability, and better align pricing incentives.
